Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit
A California federal jury on Thursday found Eli Lilly breached the implied covenant of good faith and fair dealing in an agreement to co-develop Nektar Therapeutics' autoimmune-disease drug Rezpeg, awarding Nektar...To view the full article, register now.
Already a subscriber? Click here to view full article